NCT00381641 2025-03-28
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
6 trialsNCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
NCT00668811 2020-08-05
IIT Sutent
Medstar Health Research Institute
Phase 2 Completed
NCT00428220 2019-06-27
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
Phase NA Completed
NCT00519896 2017-04-25
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
University of Washington
Phase 2 Completed
NCT00510640 2013-02-28
THYSU
University Hospital, Bordeaux
Phase 2 Completed